The latest: HutchMed (China) Ltd. (HCM.US; 0013.HK) announced late Monday that its Surufatinib drug for the treatment of advanced neuroendocrine tumors was denied approval by the U.S. Food and Drug Administration (FDA).

Looking up: The FDA indicated its denial was not related to any safety issues, but instead said that additional multi-regional clinical trials (MRCTs) more representative of the U.S. patient population would be needed to support a U.S. approval.

Take Note: The FDA determined that the current data package, based on two positive Phase 3 trials in China and one bridging study in the U.S., does not support an approval in the U.S. at this time.

Digging Deeper: With treatment options very limited worldwide, the FDA granted Surufatinib with fast-track designation in April 2020 for the treatment of pancreatic and extra-pancreatic neuroendocrine tumors. In May 2020, HutchMed and the FDA agreed that the two positive Chinese Phase 3 studies of Surufatinib for the treatment of the above diseases, along with a bridging trial in the U.S., could form the basis to support a U.S. new drug application (NDA) submission. But the FDA ultimately determined the data was insufficient.

Market Reaction: HutchMed’s Hong Kong shares opened down 14.6% on Tuesday and closed down 18.5% at the midday break. They now trade at a new low of HK$20.95 following their Hong Kong IPO last June, and are down 48% from the IPO price.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

Top Toy has filed for an IPO

Will Top Toy knock Pop Mart off its throne?

China’s third largest pop toy seller, a spinoff of Japanese-style retailer Miniso, has filed for a Hong Kong IPO just five years after its founding Key Takeaways: Miniso spinoff Top…